DUX4 and acute lymphoblastic leukemia: To further confirm the selective sensitivity of ZNF384-r ALL to gilteritinib, we performed ex vivo drug-sensitivity assay in a panel of 47 primary ALL cases including three with EP300-ZNF384 fusion as well as those with ETV6-RUNX1, DUX4-r, BCR-ABL1, hyperdiploidy, and T-ALL.